TAK.US Takeda Pharmaceutical Co Ltd ADR

Healthcare Pharmaceuticals USA Stocks
21.64 USD
Close of Nov 18, 2026
13.48 21.86
Market cap
USD 69.1B
P/E
309.1x
P/B
1.49x
ROE
8.2%
Dividend yield
2.86%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is TAK.US undervalued?

Graham number

The Graham number of Takeda Pharmaceutical Co Ltd ADR cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Takeda Pharmaceutical Co Ltd ADR fundamental analysis

No fundamental analysis for Takeda Pharmaceutical Co Ltd ADR yet.

Takeda Pharmaceutical Co Ltd ADR stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gamm…

Full company profile